Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374305 · ClinicalTrials.gov registry record · Phase 2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
A Phase 2 study of Meningioma and Ependymoma, sponsored by Scott R. Plotkin, MD, PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 6
- Study locations
NCT04374305: Active Phase 2 study of Meningioma and Ependymoma, sponsored by Scott R. Plotkin, MD, PhD.
NCT04374305 is a Phase 2 study of Meningioma and Ependymoma that is active but no longer recruiting, run by Scott R. Plotkin, MD, PhD. The registered enrollment target is 100 participants, roughly in line with the 95-participant average among 21 other Meningioma trials with a reported enrollment target. The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04374305, a Phase 2 study of Meningioma and Ependymoma, is active but no longer recruiting, sponsored by Scott R. Plotkin, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2-SWN to receive new drugs throughout this study. Embedded within the Master Study are individual drug substudies. * Investigational Drug Sub-study A: Brigatinib * Investigational Drug Sub-study B: Neratinib
Primary Outcome
Radiographic response rates in target tumors according to tumor-associated criteria: * VS, non-VS, and meningiomas: Dombi criteria (2013) * Ependymomas: RECIST 1.12
Conditions Studied
Interventions
- DRUG Neratinib
- DRUG Brigatinib
Study Locations (6)
California
- UCLA Medical Center - Los Angeles
Florida
- University of Miami - Miami
Indiana
- Indiana University School of Medicine - Indianapolis
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
New York
- New York University Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-06-20 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 2 |
What the registry record for NCT04374305 still lists
NCT04374305 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 95-participant average among 21 other Meningioma trials with a reported enrollment target.
The record links to 5 conditions, with Meningioma appearing as the primary indexed condition, and to 2 interventions - of which Neratinib is the first listed.
NCT04374305 lists 6 locations in 6 states (California, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT04374305 about?
NCT04374305 is a clinical study titled "Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)". This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vesti...
What is the current status of trial NCT04374305?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-06-20. Estimated completion is 2030-12-01.
What conditions does trial NCT04374305 study?
This clinical trial studies the following conditions: Meningioma, Ependymoma, Vestibular Schwannoma, Neurofibromatosis Type 2, Non-vestibular Schwannoma.
What interventions are being tested in trial NCT04374305?
The interventions under investigation include: Neratinib (DRUG), Brigatinib (DRUG).
Who is sponsoring clinical trial NCT04374305?
This trial is sponsored by Scott R. Plotkin, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04374305 being conducted?
This trial has 6 study locations across California, Florida, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04374305's enrollment target sits among peer trials
100 7th of 21 higher than 15 of 21 other Meningioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meningioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Cabozantinib for Patients With Recurrent or Progressive Meningioma
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
ACTIVE NOT RECRUITING · Phase 2
-
Monthly SOM230C for Recurrent or Progressive Meningioma
COMPLETED · Phase 2
-
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI